文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

COVID-19 相关急性呼吸窘迫综合征体外膜氧合结局:一项逆概率加权分析

Outcomes of Extracorporeal Membrane Oxygenation in COVID-19-Induced Acute Respiratory Distress Syndrome: An Inverse Probability Weighted Analysis.
PubMed 文献 · Crit Care Explor · 2022-10-07
一句话结论多中心回顾性研究显示,COVID-19 相关 ARDS 患者接受 VV ECMO 的 60 天死亡率与非 COVID-19 ARDS 患者无显著差异(HR 1.27,95%CI 0.82-1.98,p=0.30)。

该多中心回顾性研究纳入全球 15 个 ICU 中因 ARDS 主要适应证接受 VV ECMO 的成人患者,比较 2020 年 3 月至 12 月 COVID-19 队列与 2018 年 1 月至 2019 年 7 月非 COVID-19 ARDS 队列。共 193 例 COVID-19 患者接受 VV ECMO,主要适应证为难治性低氧血症(孤立或合并难治性高碳酸血症),最常见并发症为出血、额外感染事件或急性肾损伤。28 天死亡率为 35%,60 天死亡率为 45%;2020 年第一波与第二波 COVID-19 之间死亡率无差异。经逆概率加权校正预设混杂因素后,COVID-19 与非 COVID-19 ARDS 患者的 60 天死亡率相等(HR 1.27;95%CI 0.82-1.98;p=0.30)。

要点

  • COVID-19 相关 ARDS 患者接受 VV ECMO 的 28 天死亡率为 35%,60 天死亡率为 45%。
  • 2020 年第一波与第二波 COVID-19 之间,接受 VV ECMO 患者的死亡率无差异。
  • 经逆概率加权后,COVID-19 与非 COVID-19 相关 ARDS 接受 VV ECMO 的 60 天死亡率相等(HR 1.27;95%CI 0.82-1.98;p=0.30)。
  • VV ECMO 主要适应证为难治性低氧血症,孤立或合并难治性高碳酸血症。
  • 发生率最高的并发症包括出血、额外感染事件或急性肾损伤。

适用人群与场景

  • 全球 15 个 ICU 的成人患者(>18 岁),因 ARDS 为主要适应证接受 VV ECMO。
  • COVID-19 队列:2020 年 3 月至 2020 年 12 月;非 COVID-19 ARDS 对照队列:2018 年 1 月至 2019 年 7 月。

研究设计与关键结果

  • 研究类型:多中心回顾性研究,共 15 个 ICU 参与。
  • 研究人群:193 例 COVID-19 患者接受 VV ECMO。
  • 主要适应证:难治性低氧血症,孤立或合并难治性高碳酸血症。
  • 并发症:发生率最高的包括出血、额外感染事件或急性肾损伤。
  • 主要结局:28 天死亡率为 35%,60 天死亡率为 45%。
  • 亚组比较:2020 年第一波与第二波 COVID-19 之间死亡率无差异。
  • 组间比较:COVID-19 与非 COVID-19 相关 ARDS 接受 VV ECMO 的 60 天死亡率相等(HR 1.27;95%CI 0.82-1.98;p=0.30)。

证据类型、等级与局限

  • 证据类型:多中心回顾性研究。
  • 校正方法:采用逆概率加权(IPW)分析校正预设混杂变量。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,COVID-19 患者接受 VV ECMO 的死亡率与其他 COVID-19 队列报告相似,且经 IPW 校正后死亡率与 ARDS 病因无关。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

UNLABELLED: Although venovenous extracorporeal membrane oxygenation (VV ECMO) has been used in case of COVID-19 induced acute respiratory distress syndrome (ARDS), outcomes and criteria for its application should be evaluated.

OBJECTIVES: To describe patient characteristics and outcomes in patients receiving VV ECMO due to COVID-19-induced ARDS and to assess the possible impact of COVID-19 on mortality.

DESIGN SETTING AND PARTICIPANTS: Multicenter retrospective study in 15 ICUs worldwide. All adult patients (> 18 yr) were included if they received VV ECMO with ARDS as main indication. Two groups were created: a COVID-19 cohort from March 2020 to December 2020 and a "control" non-COVID ARDS cohort from January 2018 to July 2019.

MAIN OUTCOMES AND MEASURES: Collected data consisted of patient demographics, baseline variables, ECMO characteristics, and patient outcomes. The primary outcome was 60-day mortality. Secondary outcomes included patient characteristics, COVID-19-related therapies before and during ECMO and complication rate. To assess the influence of COVID-19 on mortality, inverse probability weighted (IPW) analyses were used to correct for predefined confounding variables.

RESULTS: A total of 193 patients with COVID-19 received VV ECMO. The main indication for VV ECMO consisted of refractory hypoxemia, either isolated or combined with refractory hypercapnia. Complications with the highest occurrence rate included hemorrhage, an additional infectious event or acute kidney injury. Mortality was 35% and 45% at 28 and 60 days, respectively. Those mortality rates did not differ between the first and second waves of COVID-19 in 2020. Furthermore, 60-day mortality was equal between patients with COVID-19 and non-COVID-19-associated ARDS receiving VV ECMO (hazard ratio 60-d mortality, 1.27; 95% CI, 0.82-1.98; p = 0.30).

CONCLUSIONS AND RELEVANCE: Mortality for patients with COVID-19 who received VV ECMO was similar to that reported in other COVID-19 cohorts, although no differences were found between the first and second waves regarding mortality. In addition, after IPW, mortality was independent of the etiology of ARDS.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Raasveld SJ, Taccone FS, Broman LM, et al. Outcomes of Extracorporeal Membrane Oxygenation in COVID-19-Induced Acute Respiratory Distress Syndrome: An Inverse Probability Weighted Analysis. Crit Care Explor. 2022. PMID: 36248318. doi:10.1097/CCE.0000000000000770

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。